Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

NCT00128102 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

661

Enrollment

INDUSTRY

Sponsor class

Conditions

Mesothelioma
Lung Cancer

Interventions

DRUG: Vorinostat
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC